Information Provided By:
Fly News Breaks for May 26, 2016
SRPT
May 26, 2016 | 08:39 EDT
Baird said the FDA delay on Sarepta's eteplirsen drug incrementally increases the probability of approval, but more meaningfully decreases the likelihood of a complete response letter that requires a randomized placebo controlled study. The firm believes political pressures may be pushing the FDA toward a compromise. Baird maintained its Outperform rating and $23 price target on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT